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Abstract
Objective—Overexpression of transforming growth factor-beta 2 has been associated with
craniosynostosis and resynostosis following surgery. We examined the effects of localized
transforming growth factor-beta 2 inhibition on craniofacial phenotype in rabbits with
craniosynostosis.
Design—Twenty-five New Zealand white rabbits with bilateral coronal craniosynostosis were
divided into three treatment groups: (1) suturectomy control (n = 8); (2) suturectomy with
nonspecific, control immunoglobulin G antibody (n = 6); and (3) suturectomy with anti–transforming
growth factor-beta 2 antibody (n = 11). At 10 days of age, a coronal suturectomy was performed on
all rabbits. The sites in groups 2 and 3 were immediately filled with a slow-resorbing collagen gel
mixed with either immunoglobulin G or anti–transforming growth factor-beta 2 antibody. Computed
tomography scans of each rabbit were acquired at ages 10, 25, and 84 days. Craniofacial landmarks
were collected from three-dimensional computed tomography reconstructions, and growth and form
were compared among the three groups.
Results—Rabbits treated with anti–transforming growth factor-beta 2 antibody differed in form at
84 days of age compared with suturectomy control rabbits, specifically in the snout and posterior
neurocranium. Growth in some areas of the skull was greater in rabbits from the anti–transforming
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growth factor-beta 2 group than in suturectomy control rabbits, but not significantly greater than in
IgG control rabbits.
Conclusions—We find support for the hypothesis that transforming growth factor-beta 2 inhibition
alters adult form, but these changes do not appear to be localized to the suturectomy region. Slight
differences in form and growth between the two control groups suggest that the presence of the
collagen vehicle itself may affect skull growth.
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Craniosynostosis (i.e., premature fusion of one or more cranial sutures) impedes normal growth
and development of the neurocranium and may result in associated abnormalities of the
craniofacial complex (Babler, 1989; Cohen, 2000c; Richtsmeier, 2002). In humans, 95% of
brain growth is completed by 6 years of age (Enlow, 1990), by which time the metopic suture
has fused in about 90% of individuals. The remaining cranial sutures will not fuse fully until
well into adulthood (Cohen, 2000b). The full impact of craniosynostosis on neurological
development is not well understood. The early closure of even a single suture is widely thought
to increase intracranial pressure (ICP) (Renier, 1989; Gault et al., 1992; Campbell et al.,
1995; Thompson et al., 1995; Pollack et al., 1996; Hudgins et al., 1998; Mooney et al.,
1998a, 1999; Jane and Persing, 2000; Fellows-Mayle et al., 2004), although this finding has
been questioned because normative ICP data are rare (Cohen and Persing, 1998; Mouradian,
1998) and accurately assessing continuous ICP recordings is problematic (Eide et al., 2002).
Simple, nonsyndromic craniosynostosis occurs at a frequency estimated at 300 to 500 per
1,000,000 live births, of which approximately one fifth are instances of coronal suture
synostosis (Cohen, 2000a). Calvarial growth generally is impeded in the direction
perpendicular to the affected suture and is enhanced in the parallel direction (Virchow, 1851;
Jane and Persing, 2000). In bilateral coronal suture synostosis, these altered growth patterns
produce a characteristically brachycephalic shape of the head: anteroposteriorly shortened,
mediolaterally widened, and superoinferiorly expanded (Jane and Persing, 2000). Extreme
brachycephaly resulting from coronal suture synostosis is observed both in humans (Delashaw
et al., 1989) and in rabbits (Mooney et al., 1994b; Burrows et al., 1999).
Congenital coronal suture synostosis is well studied in the New Zealand white rabbit
(Oryctolagus cuniculus) (e.g., Mooney et al., 1994a, 1994b, 2001; Burrows et al., 1999). The
coronal suture starts to fuse by 21 days of gestation (Mooney et al., 1996), and the anterior
fontanelle and coronal suture are obliterated by 10 days of age in rabbits affected by early-
onset coronal suture fusion (Mooney et al., 1994b). A slightly elevated bony ridge along the
suture and frontal “bossing” also are observed, with shortening and widening of the cranial
vault. In extreme cases, Mooney et al. (1994b) have reported the occurrence of “midfacial
hypoplasia resulting in malocclusion and incisal overgrowths” (p. 3). A morphometric study
by Burrows et al. (1999) found that in adult rabbits with unoperated, complete coronal
synostosis, the cranial vault was significantly shorter than in unaffected individuals, and the
parietal and frontal bones were shorter and wider.
Current treatment protocols for craniosynostosis in humans typically include some formof
neurocranial surgery. Surgical therapy in coronal craniosynostosis routinely involves complete
remodeling of the skull, due to the ineffectiveness of strip craniectomy in producing a normal
head shape, although other surgical techniques have grown in popularity in recent years (Jane
and Persing, 2000; Yano et al., 2006; Clayman et al., 2007). Even after total reconstruction of
the skull, the area representing the suture may re-fuse shortly after surgery, requiring further
surgical correction in some cases (Mommaerts et al., 2001; Panchal and Uttchin, 2003). Given
the invasiveness of such procedures and the morbidity associated with craniofacial surgery, it
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would be advantageous to be able to prevent resynostosis and to reduce the likelihood of
additional surgical procedures. Advances in understanding the etiology of craniosynostosis
offer hope for more effective treatments.
Studies by Roth et al. (1997a, 1997b), Opperman et al. (1997, 2000), and others (Lin et al.,
1997; Poisson et al., 2004; Lee et al., 2006) indicate that overexpression of transforming growth
factor-beta 2 (Tgf-β2)1 may be associated with premature suture fusion in humans and in
animal models. Tgf-β2 is one in a family of growth regulatory molecules secreted by the dura
mater that control osteogenic processes in cranial sutures (Cohen, 2000d; Warren and
Longaker, 2001; Opperman and Ogle, 2002; Cohen, 2003). Although the pathogenesis of
simple, nonsyndromic craniosynostosis is not well understood, Loeys et al. (2005) show that
mutations in TGF-β receptor 1 and 2 are associated with some cases of craniosynostosis in
humans, and experimental manipulations of Tgf-β isoforms in various studies (Mehrara et al.,
2002; Chong et al., 2003) corroborate their importance in maintenance of cranial suture patency
and fusion. Specifically, inhibition of Tgf-β2 using neutralizing antibodies in rat calvariae has
successfully rescued normally fusing sutures from obliteration in vitro (Opperman et al.,
1999; Moursi et al., 2003).
Building upon this previous work, we explored how treatment to inhibit Tgf-β2 at the
suturectomy site affects growth of the neurocranium in a rabbit model in vivo. Using the same
rabbit colony, Mooney et al. (2007a) demonstrated that anti–Tgf-β2 treatment delays
postoperative resynostosis of the coronal suture. They also showed that, as expected, more
cranial growth occurs in the anteroposterior (A–P) direction, and intracranial volume is
significantly higher by 84 days of age than without antibody treatment (Mooney et al.,
2007b). The present study is the first quantitative, three-dimensional comparison of overall
craniofacial phenotype in these antibody treatment groups. The results of intracranial volume
comparisons, two-dimensional measurements of lateral radiographs, and histology of suture
tissue strongly suggest that significant differences in craniofacial growth occur in treated
rabbits. We expected to find differences in form and growth associated with prolonged suture
patency, particularly in the cranial vault (i.e., in the vicinity of the coronal suture).
Specifically, we hypothesized that anti–Tgf-β2–treated rabbits would exhibit less
compensatory mediolateral and dorsoventral growth of the cranial vault than occurred in the
control subjects. Additionally, the increased A–P growth of the skull demonstrated previously
in treated rabbits (Mooney et al., 2007b) should be localized to the neurocranium. To test these
hypotheses experimentally, we used three-dimensional landmark coordinate data obtained
from computed tomography (CT) scans to compare the phenotype of three groups of
craniosynostotic rabbits at two points following treatment.
MATERIALS AND METHODS
Sample
Twenty-five New Zealand white rabbits (O. cuniculus) with familial, early onset, bilateral
coronal suture synostosis were considered in this study. All rabbits were born in the ongoing
breeding colony of congenitally synostosed rabbits at the University of Pittsburgh in the
Department of Anthropology vivarium. The synostosed rabbits from this colony share
important morphological features with human infants exhibiting congenital bicoronal
craniosynostosis. Phenotypically, these rabbits show bony bridging at the coronal sutures as
early as 21 days gestation, obliterated coronal sutures at birth, coronal ridging, and
1We have adopted the convention used by Moursi et al. (2003) in abbreviating both the gene product and antibody against it with only
the first letter capitalized: Tgf-β2.
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brachycephalic cranial vaults by 10 days of age, and secondary changes in the cranial base,
brain, and intracranial volume by 42 days of age (Mooney et al., 1994a, 1994b, 1998b, 2002).
Because this species displays very minimal sexual dimorphism (Fox, 1994), individuals were
selected and studied without regard to sex. Rabbits were assigned randomly to one of three
treatment groups: (1) suturectomy with no treatment, which served as the surgical control group
(n = 8); (2) suturectomy with nonspecific, control immunoglobulin G (IgG) antibody in a slow-
release collagen vehicle, which served as the antibody control group (n = 6); and (3)
suturectomy with anti–Tgf-β2 antibody in a slow-release collagen vehicle, which served as the
treatment group (n = 11). This study was reviewed and approved by the University of Pittsburgh
Institutional Animal Care and Use Committee.
Surgery
At approximately 10 days of age (range = 8 to 13 days), all rabbits were anesthetized with an
intramuscular (IM) injection (0.59 mL/kg) of a solution of 91% Ketaset (ketamine
hydrochloride, 100 mg/mL; Aveco Co., Inc., Fort Dodge, IA) and 9% Rompun (xylazine, 20
mg/mL; Mobay Corp., Shawnee, KS). The scalps were then shaved, depilated, and prepared
for surgery. The calvariae were exposed using a midline scalp incision, and the skin reflected
laterally to the supraorbital borders. All animals received postoperative IM injections (2.5 mg/
kg) of Baytril (Bayer Corp., Shawnee Mission, KS) as a prophylaxis for infection. A 3-mm–
long by 15-mm–wide strip of frontal and parietal bones, including the entire length and width
of the synostosed coronal suture, was extirpated and removed in one piece from pterion to
pterion using a cutting burr. Care was taken to preserve the meningeal (fibrous) layer of the
dura and the regional vascularity.
Rabbits in the suturectomy control group received a suturectomy only. The periosteal and skin
incisions were then closed with 4-0 resorbable Vicryl suture (Ethicon, Somerville, NJ). For
rabbits in the other two groups, the suturectomy sites were filled immediately with 0.1 mL of
a slow resorbing collagen gel mixed with either IgG antibody (100 µg/suture) or anti–Tgf-β2
antibody (100 µg/suture). The collagen vehicle was a highly purified, slow-resorbing (>63 days
in rabbit perisutural tissues [Moursi et al., 2003; Mooney et al., 2004]), bovine collagen type
I gel and was provided by NeuColl, Inc. (Campbell, CA). The gel is approved by the U.S. Food
and Drug Administration for human subdermal application and was supplied at a density of 65
mg/mL, which is much higher than other collagen gels (Moursi et al., 2003; Mooney et al.,
2004). The IgG antibody is available commercially from R & D Systems (affinity purified
polyclonal antibody, catalog no. G-101-CABS; Minneapolis, MN). The anti–Tgf-β2 antibody
also was obtained from R & D Systems (affinity purified polyclonal antibody, catalog no.
AF-302-NA; neutralization data and other details available from the manufacturer at
www.rndsystems.com). The antibodies were mixed, under sterile conditions, with 100 µL
aliquots of the collagen gel to a final concentration of 100 µg per gel aliquot in a 1-mL syringe.
This volume ensured that the entire suturectomy site was filled with vehicle and antibody.
Following injections, the periosteal and skin incisions were closed with 4-0 resorbable Vicryl
suture (Ethicon).
Data Collection
Within 2 days following surgery (range = 9 to 14 days old), CT scans were acquired of each
rabbit in the sagittal plane using a GE HiSpeed Advantage Scanner (display field of view =
24.0 to 18.0 cm; mA = 120 to 150; kV = 120) at a thickness of 1 mm (10-day scan). Three-
dimensional CT scans were taken with the rabbits tranquilized with an IM injection (0.40 mL/
kg) of a solution of 91% Ketaset (ketamine hydrochloride, 100 mg/ml; Aveco) and 9% Rompun
(xylazine, 20 mg/mL; Mobay). Approximately 2 weeks later (range = 21 to 27 days old), rabbits
were rescanned (25-day scan). Finally, scans were obtained at approximately 84 days of age
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(84-day scan), by which time 80% to 90% of calvarial and brain growth is completed in the
rabbit (Harel et al., 1972; Mooney et al., 1994a, 2001, 2002).
The visualization and analysis software eTDIPS
(http://clinicalcenter.nih.gov/cip/software/etdips/) was used to produce three-dimensional
reconstructions of rabbit skulls from CT slice images (Fig. 1). Nineteen bony landmarks (Fig.
2; Table 1) were identified and their coordinate locations were recorded from each skull using
the eTDIPS landmarking tool. (For a more detailed description of the use of eTDIPS in
collecting landmark data, see Williams and Richtsmeier [2003].) Six midline and seven paired
ectocranial landmarks were chosen, based on visibility in all age groups, accuracy, and
relevance to overall cranial morphology. The resolution of the medical CT scanner relative to
the small size and minimal ossification of juvenile rabbits limited potential landmark choices,
as well as the precision of determining landmark locations, across all age groups. For instance,
no cranial sutures were consistently visible, eliminating the possibility for landmarks to be
taken at discrete tissue intersections (e.g., bregma).
All data were collected by a single observer (B.C.F.). Before beginning primary data collection,
an error study was conducted to assess measurement error in the landmark coordinate data.
Landmark locations were recorded three separate times on each of 12 CT scan reconstructions
of 10-, 25-, and 84-day-old rabbits. The mean x-, y-, and z-coordinates from the three collection
trials were calculated for each landmark, and the standard deviation from the mean was
computed for each axis. Landmarks with standard deviations of 0.8 mm or more in the x-, y-,
or z-planes were discarded, leaving 19 landmarks for primary data collection. Following
primary data collection of these landmarks in two trials, data were checked and individual
landmarks were re-collected as needed to ensure that landmark data from the two trials differed
by less than 0.5 mm on all three axes. The average of the x-, y-, and z-coordinates from the
two digitizations was used for analysis.
Methods of Analysis
Three-dimensional coordinate landmark data were analyzed using Euclidian distance matrix
analysis (EDMA; available for download at http://getahead.psu.edu/) (Lele and Richtsmeier,
1995, 2001). Form was compared within age groups and growth trajectories were compared
between treatment groups (Table 2).
Test of Form Difference
The form of an object can be defined as “the characteristic that remains invariant under any
translation, rotation or reflection of the object” (Lele and Richtsmeier, 2001, p. 73). This
includes the concepts of both size and shape. To compare form between any two groups, EDMA
converts matrices of the three-dimensional landmark coordinate data into matrices of all
possible unique interlandmark distances. From these, a matrix of mean interlandmark distances
is computed for each sample (an average form matrix [FM]). Then the mean value of each
linear distance in a sample is compared with the corresponding mean value for the same linear
distance in the other sample as a ratio. The ratio values are contained in a form difference
matrix (FDM). A nonparametric boot-strapping algorithm estimates confidence intervals (CIs)
for each interlandmark distance in order to evaluate the null hypothesis of similarity, distance
by distance. In these analyses of form and growth, a 90% CI was constructed (α = .10, rather
than the more commonly used α = .05) because the samples are small. Although the narrower
CI increases the probability of type I error (i.e., falsely rejecting the null hypothesis of
similarity), it is a more stable estimate of the true parameter when very small sample sizes are
involved (Lele and Richtsmeier, 1995).
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Comparison of Growth Patterns
Richtsmeier and Lele (1993) defined growth pattern as “the composite of geometric changes
in structure occurring through time” (p. 382). Here, we evaluated growth patterns by
quantifying the relative change in linear distances across time. Growth patterns were
statistically compared by determining if the relative change in linear distances across time was
significantly greater (or smaller) in one treatment group relative to the other group using a
nonparametric bootstrapping procedure. EDMA does this by computing a growth matrix (GM)
that compares the FMs of a treatment group at both an earlier and a later age as a ratio (the
same calculation as the FDM in form tests). To compare relative growth against another
treatment group, GMs for both groups are used to create a growth difference matrix (GDM).
The GDM calculates a ratio of the two GMs, that is, the relative change recorded for each linear
distance over the time interval. For example, the change in each interlandmark distance
between 10 days and 84 days in the anti–Tgf-β2 group would be the numerator of a ratio
comparing that group’s growth to the change in each distance in the suturectomy control group
over the same interval (in the denominator). If the relative growth of a given distance in the
anti–Tgf-β2 group is greater over the specified time period, the ratio will be greater than 1 for
that distance. If the suturectomy control group grows more in an interlandmark distance, that
ratio will be less than 1. Collectively, these localized growth ratios enable comparison of
relative growth patterns (Richtsmeier and Lele, 1993).
RESULTS
The CT scan data were acquired as part of a larger longitudinal study, and we chose those scans
that fit our requirements for age of the individual and scan quality. Missed or unreadable scans,
the timing of scans, and the early death of some rabbits meant that more than half the sample
comprised individuals (14 of 25 rabbits) for which all three scans were not available. Thus,
sample size varied for each age group depending on the scans available within each age range
(Table 3). This also resulted in comparisons of a mixture of cross-sectional and longitudinal
data. For the purposes of analysis, data were considered to be cross-sectional. This is the default
assumption on which EDMA tests are based.
Statistical Significance
In this study, a linear distance must meet three significance criteria to be reported: (1) the mean
estimate differs by at least 3.0% between the two samples being compared, (2) the 90% CI (of
the form or growth difference ratio) for that distance excludes the value 1.0 (lower bound
≥1.010 or upper bound ≤0.990), and (3) the distance must have an average magnitude of more
than 10 mm in the smallest rabbit sample used in the comparison. These criteria attempt to
mitigate as much as possible the effects of landmark error, small sample size, and intragroup
variability.
Intergroup Form Comparisons
At the time of the 25-day scan, approximately 2 weeks after treatment, there were no
statistically significant differences in form between the suturectomy control rabbits and either
of the other two groups. The only significant differences in form between members of the anti–
Tgf-β2 treatment and IgG control groups were very small in magnitude (<5.0%; see Table 4;
Fig. 3).
By the 84-day scan, statistically significant form differences were detectable among the three
groups. Anti–Tgf-β2 rabbits differed significantly from the suturectomy control group in many
distance measures. Anti–Tgf-β2 rabbits had a longer anterior portion of the cranium—
especially in the snout and palate—and a wider posterior neurocranium (black and dotted lines
in Fig. 4). Between antibody-treated and suturectomy control rabbits, 14 distances were
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significantly different by 3.4% to 4.0%, and 27 by greater than 4.0% (see Table 5). Several
statistically significant differences in form were found between the anti–Tgf-β2 and the IgG
control groups in the anterior basicranium and posterior neurocranium, ranging from 3.0% to
4.8% in magnitude (see Table 6; white lines in Fig. 4). Finally, 84-day suturectomy controls
were significantly larger (by 4.5% to 5.0%) than IgG controls in two dimensions of the posterior
neurocranium (black lines in Fig. 5; summary statistics in Table 7).
Growth Comparisons
Form and growth were analyzed in this study, working under the hypothesis of similarity among
the three treatment groups at the time of surgery and treatment (10 days of age), although the
especially small number of useable 10-day scans precluded a statistically meaningful
verification of this assumption (particularly for the IgG control group; n = 2). As such, all 10-
day scans were pooled into a single group for growth analyses.
Growth over the first interval, from 10 to 25 days of age, did not differ significantly among
the three groups in any dimension, although the form difference ratio value was above 1.0 for
nearly all distances in comparisons of anti– Tgf-β2 rabbits with both control groups. Between
25 and 84 days, the only statistically significant difference in growth was in one distance of
the neurocranium (between landmarks 16 and 18), where the suturectomy control group grew
an average of 6.3% more than the IgG group did (a difference of about 1.25 mm; line marked
with an asterisk in Fig. 5).
Over the full duration of the study (10 to 84 days), statistically significant differences in growth
occur between anti–Tgf-β2 rabbits and the suturectomy control group. Anti–Tgf-β2 rabbits
grew significantly more than suturectomy controls in width dimensions of the posterior
cranium, as well as in length of the upper face (Table 8; Fig. 6). As in the 25- to 84-day interval,
suturectomy control individuals grew significantly more (by an average of 5.0%) than IgG
controls in a single neurocranial dimension (marked with an asterisk in Fig. 5). A single
significant difference in growth is detected in this same dimension (see asterisk in Fig. 5)
between anti–Tgf-β2 and IgG control individuals over the study period. The rabbits receiving
anti–Tgf-β2 treatment grew an average of 4.8% more than IgG controls in this distance, a
difference of about 1.11 mm.
DISCUSSION
The results are broadly consistent with the expectation that treatment with Tgf-β2 neutralizing
antibodies following surgical release of a prematurely fused coronal suture will result in
different three-dimensional adult form than will surgery alone in a rabbit model. The crania of
juvenile rabbits treated with anti–Tgf-β2 antibodies in a slow-release collagen vehicle are
slightly larger in several dimensions compared with both control groups by 84 days of age.
This is consistent with Mooney and colleagues’ (2007a, 2007b) findings of prolonged patency
at the coronal suture and increased intracranial volumes in rabbits treated with anti–Tgf-β2.
One caveat to this is that growth differences between anti–Tgf-β2 rabbits and those given the
nonspecific (IgG) antibody were not statistically significant, except in one distance used in
these analyses. This raises the issue of biological as opposed to statistical significance. We
have clear evidence that adult form is different in anti–Tgf-β2 rabbits than in rabbits in either
control group (corroborated by Mooney and colleagues’ [2007b] findings), so differential
growth must be occurring. The magnitude of these changes, however, must be too small to be
detectable as statistically significantly different in these samples. Thus, we can be fairly
confident that inhibition of Tgf-β2 does affect growth beyond what may be attributed to the
effects of the collagen alone, but the practical constraints of this study (including sample size
and scan resolution) do not permit a conclusive demonstration of these effects. Further
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experimental research into antibody treatment and delivery vehicles is needed to better
characterize the quantitative and qualitative effects on sutures and overall craniofacial growth.
The form differences detected in adults of the antibody treatment group are probably a result
of prolonged patency of the suturectomy site maintained through interference with Tgf-β2
binding activity and function. Although Tgf-β2 binding activity and function were not
measured in these rabbits, these data are consistent with in vitro studies that show inhibition
of normal rodent suture fusion by interfering with Tgf-β2 function (Opperman et al., 1999;
Warren and Longaker, 2001; Opperman and Ogle, 2002; Moursi et al., 2003; Mooney et al.,
2004).
Where we were able to detect increased growth in anti– Tgf-β2 compared with suturectomy
controls, the differences are not especially localized to the neurocranium, according to these
analyses. A few dimensions of increased growth in anti–Tgf-β2 individuals (see Fig. 6) may
indirectly indicate relative neurocranial lengthening compared with suturectomy controls.
There is also evidence that some of the increased growth is localized to basicranial width (Fig.
6). Contrary to our expectations, these analyses do not suggest compensatory mediolateral or
dorsoventral growth of the cranial vault (i.e., along the sagittal suture) in rabbits receiving no
antibody treatment compared with treated individuals. On the contrary, some differences in
growth suggest that the anti–Tgf-β2 group grew more in mediolateral and dorsoventral
dimensions than suturectomy controls did (Table 8; Fig. 6).
Rabbits treated with anti–Tgf-β2 exhibited longer snouts than the control groups did at 84 days,
which was not expected in a region distant from the suturectomy site itself. A plausible
explanation for this is that subtle differences detected in the cranial base may affect the way
the palate and, hence, the snout grows in the A–P direction. It is possible that in the most severe
cases of synostosis (suturectomy control rabbits), anterior extension of the snout is inhibited
by abnormal growth of the cranial base. It has been shown that completely untreated
(synostosed) rabbits are brachycephalic and can have malocclusion, compared with unaffected
individuals (Mooney et al., 1994b; Burrows et al., 1999). Antibody therapy may ameliorate
this slightly, allowing more A–P growth of the snout in the anti–Tgf-β2 group (see especially
Fig. 4; Table 5 and Table 6).
We also expected that the two control groups would be indistinguishable from one another in
form and in growth. Two lines of evidence contradict this expectation. First, IgG control rabbits
did not differ from anti–Tgf-β2 rabbits in form or growth in the same way as suturectomy
control individuals. In fact, they did not differ significantly from rabbits treated with anti–Tgf-
β2 in any dimension by 5% or more. Second, in direct comparisons of form and growth,
suturectomy control individuals appeared to be significantly larger in the posterior
neurocranium (between landmarks 16 and 18) than rabbits receiving IgG treatment (line with
asterisk, Fig. 5). The data do not provide an explanation for this apparent discrepancy.
Although we cannot construe the lack of evidence for differences with evidence for similarity,
the scarcity of differences in form or growth of the IgG group compared with either of the other
groups does suggest that the IgG individuals may exhibit a sort of “intermediate” form. Mature
(84-day) anti–Tgf-β2 rabbits are statistically significantly larger than the suturectomy control
rabbits in several distances, but only by a small magnitude (up to 6.2%, Table 5). If the IgG
control rabbits are only slightly smaller than the anti–Tgf-β2 group and slightly larger than the
suturectomy control group in these distances, then the IgG form could be a kind of intermediate
form that is not statistically significantly different from either of the other two. There is some
evidence that this is the case. Suturectomy control rabbits were somewhat smaller than IgG
control individuals for most distances of the snout and face (by 3% to 4%), despite being slightly
longer in a distance of the neurocranium, whereas anti–Tgf-β2 rabbits were somewhat larger
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than IgG control rabbits in most distances (up to 4.8%). Mooney et al. (2007a) reported similar
findings in that IgG control rabbits exhibited slightly slower reossification rates than did
suturectomy control rabbits at 25 and 42 days of age, although the differences were not
statistically significant. The authors suggested that this was probably not an effect of the IgG
but rather was due to the presence of the collagen vehicle itself in the suturectomy site, which
may have had an osteoinhibitory effect on reossification of the suturectomy site during
degradation (Mooney et al., 2007a). A recent in vitro study (Premaraj et al., 2006) also has
shown that the collagen vehicle alone had a short-term inhibitory effect on osteoblast cell
number in culture. Because the ultimate goal of this research is to inhibit postoperative
resynostosis and to improve craniofacial growth, this should not be viewed as a confounding
variable, although future studies designed to facilitate osteogenesis using various growth
factors delivered by this collagen vehicle should take this into consideration (Mooney et al.,
2004,2007a,2007b;Premaraj et al., 2006). Ideally, the effects of collagen alone should be
compared experimentally with treatment with collagen plus Tgf-β2 inhibition to delineate more
clearly the contribution of each material to bone growth.
In considering the findings of this study, it should be noted that resynostosis was still seen in
the anti–Tgf-β2 antibody treatment group before the end of the rabbit neurocranial growth
phase (~84 days of age) (Mooney et al., 2007a, 2007b). This could indicate that antibody
therapy delivered via a resorbable collagen vehicle may have only a transitory effect and
alternative methods will have to be explored for prolonged delivery of such biological therapies
(Warren et al., 2003; Mooney et al., 2004).
The results of this study and others suggest a promising role for biologically based treatments
of craniosynostosis, yet obstacles remain to the use of these therapies in humans (Mooney et
al., 2004, 2007a, 2007b). Foremost among these obstacles is the duration of delivery of
bioreactive agents necessary for clinical utility. Humans achieve approximately 90% of their
total brain growth by 2 years of age (Enlow, 1990), compared with rabbits requiring just a few
weeks. In humans, therapeutic agents would have to be delivered in multiple doses using
existing technologies (Boyan et al., 1999; Alsberg et al., 2001, 2002; Franceschi, 2005;
Premaraj et al., 2005) or via a novel, slow-release vehicle that would last long enough to have
a therapeutic effect on neurocranial growth.
CONCLUSION
These results support our initial hypothesis that antibody treatment would change craniofacial
growth in this rabbit model. However, the study does not conclusively isolate significant
growth effects of treatment to Tgf-β2 inhibition. We did not find evidence for a reduction in
the relative magnitude of mediolateral and dorsoventral growth of the neurocranium in rabbits
treated with anti–Tgf-β2 compared with those receiving suturectomy only. We also found little
evidence that growth increases in anti–Tgf-β2 rabbits are localized to the suturectomy region.
Nonetheless, our findings corroborate previous studies in suggesting that biologically based
therapy may be a potential adjunct to the surgical treatment of infants with craniosynostosis
(Kwan et al., 2007), particularly once the technological aspects of delivery systems and gene
therapy are improved.
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Example three-dimensional (3D) reconstructions and CT slice data showing landmark
identification. The example landmark on the posterior tip of the zygomatic bone is identified
at each age, illustrating how landmarks are located using both 3D reconstructions and two-
dimensional slice images in concert. Note the differences in overall size and extent of
ossification at the three ages. A through C: Reconstructions of medical CT scans of rabbits
used in this study at (A) 10 days, (B) 25 days, and (C) 84 days (scale bar: 1 cm). a through c:
Coronal CT slice images corresponding to the reconstructions at (a) 10 days, (b) 25 days, and
(c) 84 days (not to scale). Note: Each skull represents a single scan from our data sample and
is not intended to reflect a mean form.
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Landmarks used in this study (see descriptions in Table 1), shown (from left) on lateral oblique,
postero-dorsal, and ventral views of a CT reconstruction. For clarity, only midline and left-
side landmarks are pictured here on an 84-day rabbit, although all landmarks were taken
bilaterally (19 total) on all three age groups.
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Form differences between 25-day anti-Tgf-β2 and IgG control rabbits. Dorso-caudal view of
skull. All lines represent distances in which anti–Tgf-β2 rabbits were larger than IgG control
individuals. Magnitude of difference is indicated along each distance.
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Form differences between 84-day anti–Tgf-β2 rabbits and the two control groups. All lines
represent distances that were greater in the anti–Tgf-β2 sample. Black lines indicate distances
that were greater in the anti–Tgf-β2 sample than in suturectomy controls. White lines indicate
distances that were greater in anti–Tgf-β2 rabbits than in IgG controls. Dotted lines indicate
where the distance passes through bone. Magnitude of difference is indicated along each
distance.
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Form differences between suturectomy control and IgG control rabbits at 84 days. Black lines
represent distances that were larger in suturectomy control individuals, whereas striped lines
represent distances that were larger in IgG controls. Magnitude of difference is indicated along
each distance. The distance marked with an asterisk (*) indicates the lone distance in which a
significant difference in growth is detected: (1) over the 25- to 84-day interval and 10- to 84-
day interval in suturectomy control and IgG control rabbits, and (2) over the 10- to 84-day
interval in anti–Tgf-β2 and IgG control rabbits.
Frazier et al. Page 18














Growth differences from 10 to 84 days. The anti–Tgf-β2 group grew significantly more than
the suturectomy control group did in the illustrated distances. Dotted lines indicate where the
distance passes through bone. Magnitude of difference is indicated along each distance.
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TABLE 1
Craniofacial Landmarks Used in This Study*
1. Left superior angle of incisive bone
2. Left lacrimal process of lacrimal bone
3. Left rostral supraorbital incisure
4. Left neck of zygomatic process of temporal bone, posterior aspect
5. Left posterior point of zygomatic bone
6. Left lateral occipital protuberance
7. Opisthion
8. Anterior junction of palatine fissures
9. Anterior point of intermaxillary suture
10. Posterior point of interpalatal suture
11. Left anterior junction of tympanic bulla and basal part of occipital
12. Basion
13. Right superior angle of incisive bone
14. Right lacrimal process of lacrimal bone
15. Right rostral supraorbital incisure
16. Right neck of zygomatic process of temporal bone, posterior aspect
17. Right posterior point of zygomatic bone
18. Right lateral occipital protuberance
19. Right anterior junction of tympanic bulla and basal part of occipital
*
Numbers correspond to those in Figure 2. All landmarks were taken bilaterally, making 19 total. Only left-side and midline landmarks are pictured
in Figure 2.
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TABLE 2
Comparisons and Sample Sizes Described in This Study*





anti–Tgf-β2 (7) versus IgG
control (6)
anti–Tgf-β2 (8) versus IgG
control (5)
suturectomy control (6) versus
IgG control (6)
suturectomy control (7)
versus IgG control (5)












anti–Tgf-β2 (7,8) vs. IgG
control (6,5)







   (6,5)
suturectomy control (7)
versus IgG control (5)
*
Sample sizes for each age and treatment group are noted in parentheses.
†
The 10-day-old rabbits were pooled into a single group, n = 14. See “Materials and Methods” for further explanation.
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TABLE 3
Sample Size for Each Age and Treatment Group, Based on Computed Tomography Scan Quality and Availability
Anti-Tgf-β2 Suturectomy Control IgG Control
Total individuals 11 8 6
10-day scans 5 7 2
25-day scans 7 6 6
84-day scans 8 7 5
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TABLE 4











6 to 17 Posterior neurocranium 25.72 24.83 3.60
7 to 17 Posterior neurocranium 22.40 21.67 3.40
5 to 18 Posterior neurocranium 25.65 24.80 3.40
5 to 6† Posterior neurocranium 20.87 20.21 3.20
*
Each distance is indicated by its endpoints (landmark numbers correspond to those in Table 1). Distances are illustrated in Figure 3.
†
This distance was also significantly different by 3.20% on the right side of the skull.
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TABLE 5












2 to 4 upper face 23.01 21.65 6.2
5 to 11 lateral basicranium 16.40 15.55 5.5
3 to 8† rostrum 41.96 39.86 5.4
5 to 12 lateral basicranium 25.09 23.82 5.4
10 to 8 palate 26.79 25.46 5.3
4 to 8 face 51.03 48.60 5.0
4 to 11 lateral basicranium 19.50 18.59 5.0
5 to 7 posterior cranium 24.83 23.67 5.0
14 to 11 midcranial height 38.32 36.55 4.8
14 to 10 face 21.91 20.91 4.8
2 to 11 midcranial height 32.96 31.46 4.7
5 to 6 posterior neurocranium 22.59 21.61 4.6
11 to 8† basicranium 48.51 46.42 4.5
19 to 5 basicranium 26.46 25.37 4.4
14 to 3 upper face 27.37 26.21 4.4
16 to 8 face 51.19 49.07 4.4
11 to 9 basicranium 32.65 31.27 4.3
18 to 5 posterior neurocranium 29.54 28.39 4.2
13 to 4 face 55.72 53.48 4.2
13 to 11 cranial length 54.73 52.53 4.2
4 to 10 facial depth 27.81 26.70 4.2
4 to 9 facial depth 34.54 33.15 4.2
11 to 10 basicranium 22.97 22.05 4.1
3 to 10 facial depth 23.25 22.36 4.1
3 to 9 facial depth 25.75 24.76 4.1
*
Each distance is indicated by its endpoints (landmark numbers correspond to those in Table 1). Distances in bold are illustrated by the black lines
in Figure 4.
†
These distances were also significantly different by a comparable amount on the right side.
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TABLE 6












16 to 18 posterior neurocranium 24.33 23.22 4.8
11 to 9† basicranium 32.65 31.28 4.2
11 to 10 basicranium 22.97 22.03 4.1
5 to 11 lateral basicranium 16.40 15.78 4.0
5 to 7 posterior cranium 24.83 23.87 4.0
12 to 9 basicranium 42.81 41.13 3.9
16 to 6 posterior neurocranium 30.15 29.00 3.9
4 to 11 lateral basicranium 19.50 18.78 3.9
11 to 8† basicranium 48.51 46.70 3.8
2 to 11† midcranial height 32.96 31.74 3.8
15 to 12 midcranial height 40.27 38.74 3.8
12 to 10 basicranium 32.93 31.69 3.7
12 to 8 basicranium 58.19 56.02 3.7
18 to 5 posterior neurocranium 29.54 28.54 3.6
19 to 10 basicranium 22.88 22.05 3.6
5 to 6 posterior neurocranium 22.60 21.85 3.4
5 to 12† lateral basicranium 25.09 24.23 3.4
1 to 12† cranial length 64.37 62.26 3.3
13 to 11 cranial length 54.73 52.95 3.3
14 to 12 midcranium 44.93 43.58 3.0
*
Distances in bold are illustrated by the white lines in Figure 4.
†
This distance was also significantly different on the right side of the skull (similar magnitude).
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TABLE 7













16 to 18 posterior neurocranium 24.37 23.22 5.0
6 to 16 posterior neurocranium 30.32 29.00 4.5
1 to 15† rostrum 42.68 44.24 3.8
11 to 19† cranial base 11.06 11.80 7.1
*
Distances are illustrated in Figure 5.
†
Note that in these two distances, IgG control rabbits are larger than suturectomy controls at 84 days (striped lines in Fig. 5).
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